Cadent Therapeutics Announces Poster Presentation at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced a poster presentation of its lead cognitive disorder asset CAD-9303, a positive allosteric a novel, first-in-class, positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors.

The poster, titled "NMDA Receptor Positive Allosteric Modulator CAD-9303 Reverses Mismatch Negativity and Behavioral Impairments in Pharmacological Models of NMDA Receptor Hypofunction," highlights nonclinical observations that CAD-9303 suggests a therapeutic potential to restore early auditory processing and cognitive function impaired by NMDAr hypofunction in patients with schizophrenia.

The poster will be presented on Tuesday, December 10, 2019, from 5:30 PM to 7:30 PM at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP) taking place December 8-11 in Orlando, Florida.

About Cadent Therapeutics

Cadent Therapeutics is creating therapies for the treatment of movement, mood, and cognitive disorders. The company combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators to treat spinocerebellar ataxia, essential tremor, and schizophrenia. The company has an exclusive license and collaboration agreement with Novartis to develop a negative allosteric modulator, now in Phase 2 for the treatment of treatment resistant depression. Investors include Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, Novartis Corporate and Slater Technology Fund. For more information, please visit cadenttx.com.